<DOC>
	<DOC>NCT00224081</DOC>
	<brief_summary>This study explores the safety and efficacy of intravenous iron therapy in anemic hemodialysis patients treated with epoetin alfa, who have higher serum ferritin levels, but low to normal transferrin saturation.</brief_summary>
	<brief_title>DRIVE Trial (Dialysis Patients' Response to Intravenous [IV] Iron With Elevated Ferritin)</brief_title>
	<detailed_description />
	<mesh_term>Anemia, Iron-Deficiency</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure, Chronic</mesh_term>
	<mesh_term>Ferric gluconate</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>Chronic hemodialysis Elevated serum ferritin with low to normal transferrin saturation (TSAT) Moderate to severe anemia Receiving epoetin alfa treatment Known sensitivity to FerrlecitÂ® Medical conditions that would confound the efficacy evaluation Recent blood transfusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>iron deficiency anemia</keyword>
	<keyword>ferritin</keyword>
	<keyword>hemodialysis</keyword>
	<keyword>sodium ferric gluconate</keyword>
	<keyword>epoetin alfa</keyword>
</DOC>